STOCK TITAN
  1. Home
  2. News
  3. JAGX

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

News
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Rhea-AI Summary
Napo Pharmaceuticals, a Jaguar Health company, announced that the last patient has completed their final visit for the stage 1 primary endpoint treatment period of Napo's Phase 3 OnTarget trial. The trial is studying the preventive treatment of diarrhea in adult cancer patients with solid tumors receiving targeted therapy. Top-line results for the primary endpoint are expected in late October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
clinical trial
-
News
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Rhea-AI Summary
Napo Pharmaceuticals, a Jaguar Health family company, conducted surveys that revealed the severity and impact of diarrhea associated with a commonly used ALS drug may be higher than previously understood. 87% of neurologists reported moderate to severe diarrhea, with over half stopping patient use of the drug. 93% of ALS patients and caregivers rated the severity of diarrhea as moderate or higher, with almost half stopping the drug. Napo's Phase 3 clinical trial of crofelemer aims to prevent diarrhea in cancer patients and results are expected in late October.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
-
News
Jaguar Health Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Jaguar Health reports a 36% increase in net revenue for Q2 2023 compared to Q1 2023. Top line results for the phase 3 OnTarget trial of crofelemer expected in late October 2023. The company is supporting proof-of-concept studies for crofelemer in rare disease indications. Jaguar to host investor webcast on August 14th regarding Q2 2023 financials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
earnings
News
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.12%
Tags
earnings
-
News
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.12%
Tags
none
-
News
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Rhea-AI Summary
Napo Pharmaceuticals announces FDA activation of IND application for crofelemer powder for MVID treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
News
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX): Jaguar Health announced promising results from a pilot phase 2 study of crofelemer for managing neratinib-associated diarrhea in HER2+ early-stage breast cancer patients. The study suggests that crofelemer, the Company's FDA approved drug, may effectively manage neratinib-induced diarrhea, potentially improving patients' comfort and adherence to cancer therapy. The results support the ongoing phase 3 OnTarget trial evaluating crofelemer's prophylactic use in adult cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
-
News
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) announced that Lisa Conte, the company's founder, president and CEO, will be presenting at an invitation-only lunch gathering of the Wall Street Wonders Investment Group in New York City on August 4, 2023. The group consists of various financial professionals and investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
conferences
-
News
REMINDER: Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton" August 5th
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
News
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Rhea-AI Summary
Jaguar Health announces FDA activation of IND application for crofelemer to treat uncontrolled diarrhea in SBS patient
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
Stock JAGX logo
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

#4732 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

JAGX Stock Data

24.94M
274.29M
1.78%
0.45%
8.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/